-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Relapsed/Refractory CLL: The Role of Cellular and Antibody-based T-cell–mediated Therapy

Program: Education Program
Session: It's a Different World: CLL 2024
Hematology Disease Topics & Pathways:
Research, Clinical trials, Translational Research, Clinical Research
Monday, December 9, 2024, 10:30 AM-11:45 AM

Arnon P. Kater, MD, PhD

Hematology, Cancer Center Amsterdam, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

Disclosures: Kater: BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Patents planned, issued or pending; Steering Committee, Research Funding; Roche/Genentech: Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Steering Committee, Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; LAVA: Membership on an entity's Board of Directors or advisory committees, Other: Patents planned, issued or pending; Steering Committee.

OffLabel Disclosure:

See more of: It's a Different World: CLL 2024
See more of: Education Program
<< Previous Presentation | Next Presentation